The UK’s National Institute for Health and Care Excellence (NICE) has updated its guidance to include adults with genetically confirmed Bardet-Biedl syndrome (BBS) for treatment with IMCIVREE (setmelanotide). This expands NHS-funded access beyond children and adolescents, recognizing the lifelong burden of hyperphagia and obesity in BBS patients. The decision follows additional clinical and real-world evidence supporting the drug’s benefits. This update allows more adults in England, Wales, and Northern Ireland to receive this treatment, improving quality of life for those affected by this rare genetic disorder.
Rhythm Pharmaceuticals' NICE guidance update is context for readers. For those tracking health stocks, 121 of 150 US health-sector stocks rose on Pluang today. Notable movers include MDLN at USD 37.50 (+10.00%, 98% buy), NUWE at USD 5.32 (-9.98%, 100% sell), and OSCR at USD 35.20 (+8.61%, 84% buy). Data as of Nov 04, 2026 19:41 WIB.
Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...
etoro has agreed to acquire LB Finanzas, a leading Argentine all-in-one financial app, to strengthen its presence in Latin America's fast-growing fintech market. LB Finanzas offers integrated investing and payment solutions, catering to Argentine ret...
JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...
KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...
Dimensional Fund Advisors Ltd. filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc as of November 3, 2026. This disclosure is part of regulatory requirements under the Takeover Code for investors holding 1% or more in relevan...
